Trial Profile
Phase 2 Multicenter Randomized Two Dose Level and Non-Inferiority Clinical Evaluation of Transrectal Administration of NX-1207 for the Treatment of BPH
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Fexapotide (Primary) ; Finasteride
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- 19 Mar 2013 Pooled analysis presented at the 28th Congress of the European Association of Urology.
- 25 May 2010 3-year follow-up results reported in a Nymox Pharmaceuticals media release.
- 18 May 2010 A 3-year follow-up of patients from this trial is nearing completion according to a Nymox Pharmaceuticals media release; final results are expected to be available in the next two weeks.